Sir,
We read with interest a recent article by Hemarajata and Humphries1 entitled ‘Ceftazidime/avibactam resistance associated with L169P mutation in the omega loop of KPC-2’, wherein the authors report a novel mutation, conferring resistance to ceftazidime/avibactam, in the omega loop of the blaKPC-2 gene of a Klebsiella pneumoniae isolate, which emerged after 12 days of combination therapy.
Following the ECDC alert,2 in an effort to prevent the spread of ceftazidime/avibactam-resistant, carbapenem-resistant Enterobacteriaceae (CRE), and in our role as regional reference centre, we began collecting and analysing all ceftazidime/avibactam-resistant isolates obtained from patients treated at our hospital as well as strains received from other hospitals of the Latium region. In this context, we would like to share the preliminary results of our ongoing study aimed at detecting the mechanisms responsible for ceftazidime/avibactam resistance in CRE.
Two K. pneumoniae strains, one susceptible (Kp-1-S) and one resistant (Kp-2-R) to ceftazidime/avibactam, were obtained from the blood cultures of a patient treated at the San Filippo Neri Hospital and were analysed at the ‘L. Spallanzani’ National Institute for Infectious Diseases in Rome. The Kp-2-R strain, which also showed decreased imipenem and meropenem MICs, was isolated after 19 days of a ceftazidime/avibactam + colistin-based treatment, which was started in order to treat bacteraemia caused by the Kp-1-S susceptible strain.
Susceptibility testing was performed using the broth microdilution method, as recommended.2 The ST of both isolates was determined by traditional MLST of seven housekeeping genes; the blaKPC alleles and porin alterations (OmpK35 and OmpK36) were investigated by Sanger sequencing.
Both isolates belonged to ST512 and harboured an insertion mutation of glycine–aspartic acid residues (GD) at amino acid positions 134–135 in the OmpK36 L3 loop, as described previously.3 No mutations were observed in OmpK35. As shown in Table 1, the MIC of ceftazidime/avibactam increased by four 2-fold serial dilutions, i.e. from 2 to 32 mg/L. Conversely, the MICs of two out of three carbapenems were markedly decreased (Table 1). BLAST analysis revealed the presence, in the blaKPC-3 gene of the ceftazidime/avibactam-resistant K. pneumoniae isolate, of the L169P mutation, which consists of a single nucleotide substitution (T to C) resulting in a leucine-to-proline amino acid substitution at amino acid position 169.
Table 1.
Antimicrobial susceptibility results for the clinical isolates described in this study
| MIC (mg/L), S/R |
|||||||||
|---|---|---|---|---|---|---|---|---|---|
| Strain | CAZ/AVI | CAZ | FEP | CTX | ETP | IPM | MEM | TZP | GEN |
| Kp-1-S | 2, S | >8, R | >8, R | >8, R | >8, R | >16, R | >16, R | >128, R | 4, S |
| Kp-2-R | 32, R | >8, R | >8, R | >8, R | >8, R | 0.5, S | 2, S | >128, R | 4, S |
CAZ/AVI, ceftazidime/avibactam; CAZ, ceftazidime; FEP, cefepime; CTX, cefotaxime; ETP, ertapenem; IPM, imipenem; MEM, meropenem; TZP, piperacillin/tazobactam; GEN, gentamicin; S, susceptible; R, resistant.
Besides mutations in the omega loop of KPC enzymes, other mechanisms of ceftazidime/avibactam resistance have been reported, such as a decrease in permeability caused by modifications in outer membrane proteins and differences in susceptibility of KPC subtypes.4–6 However, the mechanisms most often associated with resistance observed after ceftazidime/avibactam treatment are mutations in the blaKPC gene.7,8
At the time of writing, the known blaKPC mutations responsible for ceftazidime/avibactam resistance include A177E, D179Y, V240G, T243M and EL165-166.9,10 The L169P mutation that Hemarajata and Humphries1 have described in the blaKPC-2 gene and that was observed by us in blaKPC-3 is similar to D179Y (found in both blaKPC variants); both mutations result in combined ceftazidime/avibactam resistance and restoration of in vitro activity of carbapenems.
Taken together, our results support the observation that the omega loop of KPC enzymes plays a key role in the emergence of mutations arising after antibiotic therapy; further studies aiming at understanding the mechanisms of ceftazidime/avibactam resistance should probably focus on this mutation-prone region of the bacterial genome. Our data also underscore the need for active surveillance in order to prevent the spread of any ceftazidime/avibactam-resistant strains that emerge during treatment.
Funding
This work was supported by ‘Ricerca corrente’ and ‘5X1.000’ research funds from the Italian Ministry of Health.
Transparency declarations
None to declare.
References
- 1. Hemarajata P, Humphries RM.. Ceftazidime/avibactam resistance associated with L169P mutation in the omega loop of KPC-2. J Antimicrob Chemother 2019; 74: 1241–3. [DOI] [PubMed] [Google Scholar]
- 2.ECDC. Emergence of Resistance to Ceftazidime-Avibactam in Carbapenem-Resistant Enterobacteriaceae—12 June 2018. Stockholm, Sweden: ECDC, 2018. [Google Scholar]
- 3. Wise MG, Horvath E, Young K. et al. Global survey of Klebsiella pneumoniae major porins from ertapenem non-susceptible isolates lacking carbapenemases. J Med Microbiol 2018; 67: 289–95. [DOI] [PubMed] [Google Scholar]
- 4. Humphries RM, Yang S, Hemarajata P. et al. First report of ceftazidime-avibactam resistance in a KPC-3-expressing Klebsiella pneumoniae isolate. Antimicrob Agents Chemother 2015; 59: 6605–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Shields RK, Potoski BA, Haidar G. et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis 2016; 63: 1615–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Shields RK, Clancy CJ, Hao B. et al. Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum β-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae. Antimicrob Agents Chemother 2015; 59: 5793–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Giddins MJ, Macesic N, Annavajhala MK. et al. Successive emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in blaKPC-2-harboring Klebsiella pneumoniae sequence type 307 isolates. Antimicrob Agents Chemother 2018; 62: e02101-17. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Gaibani P, Campoli C, Lewis RE. et al. In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment. J Antimicrob Chemother 2018; 73: 1525–9. [DOI] [PubMed] [Google Scholar]
- 9. Shields RK, Chen L, Cheng S. et al. Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother 2017; 61: e02097-16. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Haidar G, Clancy CJ, Shields RK. et al. Mutations in blaKPC-3 that confer ceftazidime-avibactam resistance encode novel KPC-3 variants that function as extended-spectrum β-lactamases. Antimicrob Agents Chemother 2017; 61: e02534-16. [DOI] [PMC free article] [PubMed] [Google Scholar]